Goldman Sachs Downgrades Harmony Biosciences to Sell, Lowers Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins has downgraded Harmony Biosciences (NASDAQ:HRMY) from Neutral to Sell and lowered the price target from $40 to $31.
September 25, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs has downgraded Harmony Biosciences and lowered its price target, which could negatively impact the stock's price.
The downgrade from Neutral to Sell by Goldman Sachs, a major financial institution, could lead to a decrease in investor confidence in Harmony Biosciences. Additionally, the lowering of the price target from $40 to $31 suggests that the stock is overvalued at its current price, which could further drive down the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100